Switch Therapeutics
PrivateLast Round
Series A
Mar 14, 2023
Total Funding Raised
$71.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Switch Therapeutics operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series A round in March 2023.
Switch Therapeutics is a biotechnology company that develops biomarker-gated genetic medicines using its proprietary Conditionally Activated siRNA (CASi) platform to treat central nervous system diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Switch Therapeutics Comparables
Compare Switch Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Atalanta Therapeutics | 82% | |
| Cargene Therapeutics | 81% | |
| Cenos Therapeutics | 81% |
For institutional investors. Book with your work email.
Switch Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 14, 2023 | ||||
| Seed | Oct 4, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Switch Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCB Ventures | Series A |
| KMG Capital Partners | Seed |
| Dolby Family Ventures | Series A |
| Digitalis Ventures | Series A |
| Upfront Ventures | Series A, Seed |
| UCB Ventures | Series A |
| Freeflow Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors grew 212% MoM, reaching 1.8K.
- Mar 14, 2023
$52M round led by UCB Ventures and Insight Partners.
For institutional investors. Book with your work email.
Switch Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Switch Therapeutics's valuation, stock price, and market status.
Is Switch Therapeutics a public or private company?
Switch Therapeutics is a private company.
What is the current stock price of Switch Therapeutics?
Switch Therapeutics is a private company, so its shares have no public market price. Caplight tracks Switch Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Switch Therapeutics worth (valuation)?
Valuation information for Switch Therapeutics is not publicly available.
Can I buy Switch Therapeutics stock?
Switch Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Switch Therapeutics's last funding round?
Switch Therapeutics's most recent funding round was Series A on March 14, 2023.
Who are the main investors in Switch Therapeutics?
Key investors in Switch Therapeutics include UCB Ventures, UCB Ventures, Insight Partners.
Will Switch Therapeutics IPO soon?
No public IPO plans have been announced for Switch Therapeutics.
How can I track Switch Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Switch Therapeutics's shares on secondary markets.